Climb Bio (CLYM) Q1 2026 earnings summary

Executive summary

• Focused on developing therapeutics for immune-mediated diseases, with lead candidates budoprutug (anti-CD19 mAb) and CLYM116 (anti-APRIL mAb) in clinical development for multiple indications including pMN, ITP, SLE, and IgAN.

• Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting further development across multiple autoimmune indications.

• Multiple ongoing and planned clinical trials for budoprutug (pMN, ITP, SLE) and CLYM116, with data readouts expected throughout 2026.

• No product revenue to date; operations funded by equity offerings and private placements.

• Secured $110 million in private placement financing in April 2026, strengthening the balance sheet ahead of key data milestones.

Financial highlights

• Net loss for Q1 2026 was $13.7 million, or $(0.20) per share, compared to $20.8 million, or $(0.31) per share, in Q1 2025.

• Total operating expenses decreased to $15.2 million from $23.0 million year-over-year, mainly due to a $9.0 million upfront payment for a license agreement in Q1 2025 with no similar payment in Q1 2026.

• Cash, cash equivalents, and marketable securities totaled $146.3 million as of March 31, 2026, not including proceeds from April 2026 financing.

• Research and development expenses were $9.4 million, down from $17.3 million year-over-year.

• General and administrative expenses were $5.8 million, up slightly from $5.7 million year-over-year.

• Interest and other income was $1.5 million for Q1 2026, compared to $2.3 million in Q1 2025.

Outlook and guidance

• Cash runway expected to fund operations into 2028, excluding proceeds from the April 2026 private placement; updated guidance to be provided after evaluating recent financing.

• Initial and multiple clinical data readouts from ongoing trials for budoprutug and CLYM116 expected in mid to late 2026.